Aimble is an AI drug development company utilizing a structure-based drug design platform that integrates molecular dynamics simulation, quantum calculations, and docking techniques to identify drug candidates. The platform significantly reduces the time required for drug candidate discovery from 2-5 years to 1-2 years, addressing the high failure rates in clinical trials due to toxicity issues.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery processes are lengthy and expensive, often taking many years and requiring significant resources. High failure rates in clinical trials, frequently due to toxicity issues or lack of efficacy, further compound these challenges.
Solution
Aimble is developing an AI-driven, structure-based drug design platform that accelerates the identification of promising drug candidates. The platform integrates molecular dynamics simulation, quantum calculations, and docking techniques to analyze protein-ligand interactions at the atomic level. By leveraging physics-based modeling and AI, Aimble aims to predict drug efficacy and toxicity earlier in the development pipeline, reducing the time and cost associated with bringing new drugs to market. The platform's bottom-up approach focuses on the physical and chemical properties of compounds to identify and optimize drug candidates.
Target Audience
Aimble's primary customers are pharmaceutical companies and biotech ventures seeking to accelerate drug discovery and reduce clinical trial failure rates.
Features
- Structure-based drug design using molecular dynamics and quantum calculations
- AI-powered prediction of drug efficacy and toxicity
- Data engineering for toxicity prediction
- Drug-target binding affinity prediction
- Atomic-level analysis of protein and compound interactions
- Synthesis lab for constructing chemical compounds designed via the platform